Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Transcenta and WuXi Biologics Forge Strategic CDMO Partnership with RMB 190 Million Manufacturing Facility Transaction

Fineline Cube Aug 7, 2026
Company Deals

Biogen Completes $1 Billion Acquisition of RayThera to Bolster Immunology Portfolio with Novel Small-Molecule Pipeline

Fineline Cube Aug 7, 2026
Company Deals

Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China

Fineline Cube Aug 6, 2026
Company Deals

AstraZeneca and CSPC Pharmaceutical Establish Joint Venture for Next-Generation Biologics Manufacturing Base in Shijiazhuang

Fineline Cube Aug 6, 2026
Company Deals

Curium Pharma to Acquire Lantheus Holdings in $8 Billion Deal, Expanding Radiopharmaceutical Market Dominance

Fineline Cube Aug 5, 2026
Policy / Regulatory

China’s CDE Releases 109th Reference Listed Drug Catalog, Adding 10 New Generic Drug Specifications

Fineline Cube Aug 6, 2026
Company Drug

CARsgen Therapeutics Secures NMPA Clinical Trial Approval for Allogeneic CAR-T Therapy CT1190B in Relapsed/Refractory Large B-Cell Lymphoma

Fineline Cube Aug 7, 2026
Company Drug

Takeda Expands Revestive Approval in China with New 1.25 mg Specification for Pediatric Short Bowel Syndrome Patients as Young as 4 Months

Fineline Cube Aug 7, 2026
Company Deals

Bayer and Tsinghua University Renew Strategic Research Pact for Drug Innovation

Fineline Cube Jun 25, 2025

German pharmaceutical giant Bayer AG (ETR: BAYN) and Tsinghua University announced the signing of their...

Company Medical Device

Dynamiker Bio’s Aspergillus Detection Kit Wins NMPA Marketing Approval

Fineline Cube Jun 25, 2025

China-based Dynamiker Biotechnology (Tianjin) Co., Ltd. announced that it has received marketing approval from the...

Company Drug

GSK Gains FDA Clearance for Benlysta Autoinjector in Pediatric Lupus Nephritis

Fineline Cube Jun 25, 2025

UK-based GlaxoSmithKline (GSK; NYSE: GSK) announced that it has received clearance from the US Food...

Company Drug

Medilink Therapeutics’ YL201 Wins FDA Breakthrough Therapy Designation for SCLC

Fineline Cube Jun 25, 2025

Suzhou-based Medilink Therapeutics announced that it has received Breakthrough Therapy Designation (BTD) from the US...

Company Deals Hospital Medical Device

Siemens Healthineers Collaborates with MGH to Advance Theranostics Applications

Fineline Cube Jun 25, 2025

Siemens Healthineers AG (ETR: SHL), a Germany-based medical device giant, has entered into a research...

Company Drug

FDA Approves AstraZeneca’s Datopotamab deruxtecan for EGFR-Mutated NSCLC

Fineline Cube Jun 25, 2025

The US Food and Drug Administration (FDA) this week approved Datopotamab deruxtecan (Dato-DXd), a TROP-2-targeted...

Company Drug

TransThera Sciences’ Tinengotinib Gains FDA Fast Track for mCRPC Treatment

Fineline Cube Jun 25, 2025

China-headquartered TransThera Sciences (Nanjing) Inc., (HKG: 2617), which listed in Hong Kong this week, announced...

Company Deals Drug

XtalPi Signs LOI With DoveTree for AI-Powered Drug Development

Fineline Cube Jun 25, 2025

Shenzhen-based QuantumPharm Inc., known as Xtalpi Inc. (HKG: 2228), announced the signing of a Letter...

Company Drug

Merck’s Prevymis Approved in China for Pediatric CMV Prevention

Fineline Cube Jun 25, 2025

US-based pharmaceutical giant Merck, Sharp & Dohme (MSD, NYSE: MRK) announced that its novel non-nucleoside...

Company Drug

Sansure Biotech Wins NMPA Approval for Fungal Infection Detection Kit

Fineline Cube Jun 24, 2025

China’s National Medical Products Administration (NMPA) has approved Sansure Biotech Inc.’s (SHA: 688289) Pneumocystis jirovecii,...

Company Medical Device

Broncus Medical Wins NMPA Approval for BroncAblate RFA System Console

Fineline Cube Jun 24, 2025

Shanghai and Hangzhou (China), and San Jose and Seattle (United States)-based Broncus Medical (HKG: 2216)...

Policy / Regulatory

NHSA Implements Region-Based Pricing System for Medical Services

Fineline Cube Jun 24, 2025

China’s National Healthcare Security Administration (NHSA) this week issued the “Notice on Optimizing Medical Service...

Company Deals

Insilico Medicine Partners with UAEU to Drive Biotech Innovation in the Middle East

Fineline Cube Jun 24, 2025

China-based generative artificial intelligence (AI)-driven biotech Insilico Medicine this week entered into a strategic Memorandum...

Company Deals

Bio-Thera Partners with SteinCares for Biosimilar Commercialization in Latin America

Fineline Cube Jun 24, 2025

Guangzhou-based Bio-Thera Solutions Ltd. (SHA: 688177) and Costa Rica-based SteinCares have entered into a licensing...

Company Drug

Vcanbio Submits Clinical Trial Application for VUM02 in Severe Pneumonia Treatment

Fineline Cube Jun 24, 2025

China-based Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) announced that its clinical trial...

Company Drug R&D

Simcere Halts R&D on Alzheimer’s Drug Candidates Amid Pipeline Setbacks

Fineline Cube Jun 24, 2025

Simcere Pharmaceutical Group (HKG: 2096) has reportedly discontinued research and development of its Alzheimer’s disease...

Company Drug

Yifan Pharma Wins NMPA Approval for Norditropin Biosimilar Trial

Fineline Cube Jun 24, 2025

China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) announced that it has received clinical trial approval...

Company Drug

GSK’s Linerixibat Accepted for EMA Review for Cholestatic Pruritus in PBC

Fineline Cube Jun 24, 2025

UK-based GlaxoSmithKline (GSK; NYSE: GSK) announced that the European Medicines Agency (EMA) has accepted the...

Company Drug

Sanofi’s Sarclisa Recommended for EU Approval in Newly Diagnosed Multiple Myeloma

Fineline Cube Jun 24, 2025

France major Sanofi (NASDAQ: SNY) announced that the European Medicines Agency’s (EMA) Committee for Medicinal...

Policy / Regulatory

Beijing Tightens Price Risk Management for Scarce Medications

Fineline Cube Jun 24, 2025

The Beijing Municipal Medical Insurance Bureau issued the “Notice on Further Strengthening Price Risk Management...

Posts pagination

1 … 177 178 179 … 705

Recent updates

  • CARsgen Therapeutics Secures NMPA Clinical Trial Approval for Allogeneic CAR-T Therapy CT1190B in Relapsed/Refractory Large B-Cell Lymphoma
  • Transcenta and WuXi Biologics Forge Strategic CDMO Partnership with RMB 190 Million Manufacturing Facility Transaction
  • Takeda Expands Revestive Approval in China with New 1.25 mg Specification for Pediatric Short Bowel Syndrome Patients as Young as 4 Months
  • Hengrui Pharmaceuticals Secures Fifth NMPA Approval for Ivarmacitinib in Non-Radiographic Axial Spondyloarthritis
  • Westlake Consortium Secures NMPA Approval for Iscartrelvir, Novel Oral 3CLpro Inhibitor for Mild-to-Moderate COVID-19
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

CARsgen Therapeutics Secures NMPA Clinical Trial Approval for Allogeneic CAR-T Therapy CT1190B in Relapsed/Refractory Large B-Cell Lymphoma

Company Deals

Transcenta and WuXi Biologics Forge Strategic CDMO Partnership with RMB 190 Million Manufacturing Facility Transaction

Company Drug

Takeda Expands Revestive Approval in China with New 1.25 mg Specification for Pediatric Short Bowel Syndrome Patients as Young as 4 Months

Company Drug

Hengrui Pharmaceuticals Secures Fifth NMPA Approval for Ivarmacitinib in Non-Radiographic Axial Spondyloarthritis

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.